Oocyte and ovarian tissue cryopreservation in European countries: statutory background, practice, storage and use.
Open Access
- 29 March 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2017 (1), hox003
- https://doi.org/10.1093/hropen/hox003
Abstract
What is known in Europe about the practice of oocyte cryopreservation (OoC), in terms of current statutory background, funding conditions, indications (medical and 'non-medical') and specific number of cycles? Laws and conditions for OoC vary in Europe, with just over half the responding countries providing this for medical reasons with state funding, and none providing funding for 'non-medical' OoC. The practice of OoC is a well-established and increasing practice in some European countries, but data gathering on storage is not homogeneous, and still sparse for use. Ovarian tissue cryopreservation (OtC) is only practiced and registered in a few countries. A transversal collaborative survey on OoC and OtC, was designed, based on a country questionnaire containing information on statutory or professional background and practice, as well as available data on ovarian cell and tissue collection, storage and use. It was performed between January and September 2015. All ESHRE European IVF Monitoring (EIM) consortium national coordinators were contacted, as well as members of the ESHRE committee of national representatives, and sent a questionnaire. The form included national policy and practice details, whether through current existing law or code of practice, criteria for freezing (age, health status), availability of funding and the presence of a specific register. The questionnaire also included data on both the number of OoC cycles and cryopreserved oocytes per year between 2010 and 2014, specifically for egg donation, fertility preservation for medical disease, 'other medical' reasons as part of an ART cycle, as well as for 'non-medical reasons' or age-related fertility decline. Another question concerning data on freezing and use of ovarian tissue over 5 years was added and sent after receiving the initial questionnaire. Out of 34 EIM members, we received answers regarding OoC regulations and funding conditions from 27, whilst 17 countries had recorded data for OoC, and 12 for OtC. The specific statutory framework for OoC and OtC varies from absent to a strict frame. A total of 34 705 OoC cycles were reported during the 5-year-period, with a continuous increase. However, the accurate description of numbers was concentrated on the year 2013 because it was the most complete. In 2013, a total of 9126 aspirations involving OoC were reported from 16 countries. Among the 8885 oocyte aspirations with fully available data, the majority or 5323 cycles (59.9%) was performed for egg donation, resulting in the highest yield per cycle, with an average of 10.4 oocytes frozen per cycle. OoC indication was 'serious disease' such as cancer in 10.9% of cycles, other medical indications as 'part of an ART cycle' in 16.1%, and a non-medical reason in 13.1%. With regard to the use of OoC, the number of specifically recorded frozen oocyte replacement (FOR) cycles performed in 2013 for all medical reasons was 14 times higher than the FOR for non-medical reasons,...Keywords
This publication has 38 references indexed in Scilit:
- Fertility Preservation for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- Mature oocyte cryopreservation: a guidelineFertility and Sterility, 2013
- Oocyte cryopreservation for age-related fertility lossHuman Reproduction, 2012
- Social egg freezing: for better, not for worseReproductive BioMedicine Online, 2011
- Social egg freezing: the prospect of reproductive ‘immortality’ or a dangerous delusion?Reproductive BioMedicine Online, 2011
- Why do people postpone parenthood? Reasons and social policy incentivesHuman Reproduction Update, 2011
- Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKTArchiv für Gynäkologie, 2011
- Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte studyHuman Reproduction, 2009
- Oocyte vitrification—Women's emancipation set in stoneFertility and Sterility, 2009
- ESHRE Task Force on Ethics and Law 15: Cross-border reproductive careHuman Reproduction, 2008